This study will test a remote approach to help people who may be at higher risk for pancreatic cancer learn about and decide whether to get genetic testing and a blood test that looks for signs of several cancers (MCED testing). The study is focused on Black, Latino/a, and Medicaid-enrolled individuals who may have had less access to cancer genetics and early detection services. About 80 participants, who reside in Massachusetts, will be assigned by chance to receive either online education alone or online education plus a phone call with a trained educator from the Pancreatic Cancer Action Network (PanCAN). After the education, participants can choose whether or not to have genetic testing and/or MCED testing. The main goal is to learn whether this approach is practical to carry out, acceptable to participants, and delivered as planned. Participants will complete 3 surveys during study participation.
Aged 50 years or older OR 10 years younger than the earliest PDAC diagnosis in a family member
Current Medicaid enrollment and/or Black and/or Latino/a
Willingness to travel to Dana-Farber Cancer Institute in Boston, MA, for diagnostic testing if MCED screening test indicates possible malignancy
Living in the state of Massachusetts
Less than age 50 years or age not within 10 years of the earliest PDAC diagnosis in their family
Cancer diagnosis in the last 3 years (excluding non-melanoma skin cancers)
Currently pregnant
Insurance other than Medicaid or race/ethnicity other than Black or Latino/a
Parallel
Telephone education session
BehavioralParticipants will receive a telephone call from a trained navigator at PanCAN to provide \~20mins of information about genetic testing and MCED testing.
Online educational materials
BehavioralParticipants will receive links to test information provided by the testing company.
Feasibility of completion of genetic testing and MCED testing
The intervention will be feasible if at least 30% of enrolled participants complete germline genetic testing and at least 30% complete MCED testing.
Acceptability of the education delivery
Acceptability will be assessed using the 3-item Client Satisfaction Questionnaire-3 (CSQ-3), with a mean score of at least 3 indicating acceptable intervention acceptability.
Fidelity of the intervention
Fidelity will be considered adequate if at least 90% of participants in the telephone arm complete a session in which at least 90% of the required educational contents is reviewed
Click on the lead sponsor to view all of their trials.
Brigham and Women's Hospital
Lead sponsor
Pancreatic Cancer Action Network
Collaborator
Exact Science Corporation
Collaborator
Dana-Farber Cancer Institute
Collaborator
Winn Career Development Award
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
